Table S1. **Demographic and clinical characteristics of patients examined with global gene expression profiling, qPCR, and chemokine multiplex assays**

Characteristic	N=24
Gender, female	19 (79%)
Age at the time of first study visit, mean (SD)	49.2 (13)
Diffuse cutaneous involvement	9 (37.5%)
*Disease Duration 1, mean (SD)	3.5 (3.2)
**Disease Duration 2, mean (SD)	3.9 (3.5)
ACA	2 (8%)
ATA	9 (38%)
ARA	4 (17%)
RNP	4 (17%)

Abbreviations: ACA: Anti-centromere antibodies; ATA: Anti-topoisomerase antibodies; ARA: Anti-RNA polymerase III antibodies (ARA); RNP: Anti-U1 ribonucleoprotein antibodies.

* Disease duration 1 was calculated from the onset of the first non-Raynaud's syndrome.

**Disease duration 2 was calculated from the onset of the first symptom including Raynaud's.

Table S2. **Exclusion of the 4 patients with late SSc did not change the correlation of IFN chemokine levels with IFN transcript signature in the remaining patients (n=20)**

Chemokines	Correlation with IFN array score		Correlation with IFN qPCR score	
	p	Rho	*p*	Rho
IP-10	0.009	0.567	0.003	0.628
I-TAC	0.008	0.571	0.007	0.584
MCP-1	0.177	0.314	0.056	0.434
IP-10 & I-TAC	0.0007	0.692	<0.001	0.719
IP-10 & I-TAC &MCP-1	0.011	0.556	0.003	0.629